Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
申请人:Bacani Genesis M.
公开号:US20090111794A1
公开(公告)日:2009-04-30
Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A
4
hydrolase (LTA
4
H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA
4
H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
芳基取代的桥接或融合二胺化合物,含有它们的药物组合物,以及使用这些化合物和药物组合物进行白三烯A4水解酶(LTA4H)调节和治疗由LTA4H活性介导的疾病状态、疾病和疾病,如过敏、哮喘、自身免疫疾病、瘙痒、炎症性肠病、溃疡性结肠炎和心血管疾病,包括动脉粥样硬化和预防心肌梗死的方法。